烟碱和槟榔碱对离体大鼠海马脑片CA_1锥体细胞外诱发电位的影响

在离体Ｗｉｓｔａｒ大鼠海马脑片上,用微电极记录刺激顶树突层Ｓｃｈａｆｆｅｒ侧支引起的ＣＡ＿１区锥体细胞外群峰电位（ＰＳ）。观察用半浸式浴槽或多管微电极气压微量注射给予Ｎ受体激动剂烟碱（Ｎｉｃ）和Ｍ受体激动剂槟榔碱（Ａｒｅ）对ＰＳ的影响,探讨Ｍ和Ｎ受体功能。结果表明：Ｎｉｃ对ＰＳ幅度无明显影响,浓度１．０ｍｍｏｌ／Ｌ时约１／４脑片诱发出第二个群峰电位（ＰＳ＿２）,浓度增加,ＰＳ＿２发生率增加,ＰＳ＿２幅度较ＰＳ低。美加明能部分对抗烟碱诱发的ＰＳ＿２,表明ＰＳ＿２出现与Ｎ受休关系密切。Ａｒｅ降低ＰＳ幅度,当浓度达到０．００１ｍｍｏｌ／Ｌ即能使ＰＳ幅度降低为正常的７４％,ＰＳ幅度降低存在有效量关系,低浓度阿托品能选择性地对抗之,表明Ａｒｅ所致ＰＳ幅度下降是通过兴奋Ｍ受体的结果。     

烟碱和槟榔碱对离体大鼠海马脑片CA1锥体细胞外诱发电位…

在离全Ｗｉｓｔａｒ大鼠海马脑片上,用微电极记录刺激顶树突层Ｓｃｈａｆｆｅｒ侧支引起的ＣＡ１区锥体细胞外群峰电位（ＰＳ）。观察用半浸式浴槽或多管微电极气压微量注射给予Ｎ受体激动剂烟碱（Ｎｉｃ）和Ｍ受体激动剂槟碱（Ａｒｅ）对ＰＳ的影响,探讨Ｍ和Ｎ受体功能。结果表明：Ｎｉｃ对ＰＳ幅度无明显影响,浓度过．０ｍｍｏｌ／Ｌ时约１／４脑片诱发出第二个群峰电位（ＰＳ２）,浓度增加,ＰＳ２发生率增加,ＰＳ２幅度较Ｐ     

公雏鸡糖皮质激素受体与免疫功能的相关性

研究了用于不同剂量（７５、５０、２５、１０ｍｇ／ｋｇ）ＲＵ４８６阻断公雏鸡糖皮质激素受体１天或连续３天免疫指标变化情况。ＲＵ４８６７５和５０ｍｇ／ｋｇ阻断ＧＲ２４ｈ,公雏鸡脾淋巴细胞ＩＬ－２、ＩＦＮ诱生活性和Ｔ、Ｂ淋巴细胞增殖活性降低（Ｐ〈０．０１）,外周血淋巴细胞、单核细胞、ＡＮＡＥ＋细胞减少（Ｐ〈０．０１）;胸腺、脾脏、法氏囊的体重比减小（Ｐ〈０．０１）。每日ＲＵ４８６５０ｍｇ／ｋｇ连续３天阻     

反复摄取烟碱对脑肌醇含量的影响

急性实验中,间隔５ｍｉｎ反复注射烟碱０．５,１．０,１．０,２．０,２．０ｍｇ／ｋｇｉｐ,３０ｍｉｎ后大鼠大脑皮层及海马中肌醇含量升高,但纹状体中肌醇含量无显著变化;相同条件下,氯化锂１０ｍｍｏｌ／ｋｇｉｐ３０ｍｉｎ后大脑皮层和海马中肌醇含量显著降低;慢性实验中,烟碱２．０－１０．０ｍｇ／ｋｇｓｃｂｉｄ１４ｄ后,大鼠大脑皮层中肌醇含量显著增高;烟碱２．６９－１１．５３ｍｇ／ｋｇ／ｄｐｏ６４ｄ后,大鼠大脑皮层中肌醇含量也显著增高。表明烟碱的作用不同于氯化锂,反复给予烟碱可使大鼠大脑皮层中肌醇含量增加。     

血管紧张素II和阿片肽对Fos蛋白表达的影响

利用抗体免疫沉淀技术研究了血管紧张素ＩＩ,δ受体激动剂和ｋ受体激动剂对大鼠脑组织ｃ－ｆｏｓ原癌基因表达的影响,结果表明,０．１μｍｏｌ／Ｌ ＡⅡ可显著刺激脑组织中Ｆｏｓ蛋白的表达,０．１μｍｏｌ／ＬＤＰＤＰＥ和０．１μｍｏｌ／Ｌ ＮＤＡＰ对Ｆｏｓ蛋白的表达亦有一定的诱导作用。ＡＩＩ与ＤＰＤＰＥ或ＮＤＡＰ共同处理组织,Ｆｏｓ蛋白表达水平低于ＡＩＩ单独诱导的水平,结果表明阿片肽可抑制ＡＩＩ对Ｆｏｓ蛋白     

低分子量硫酸葡聚糖对小鼠造血干细胞动员作用的研究

给小鼠静脉注射低分子量（＜１０￣４ｕ）硫酸葡聚糖（ＤＳ）１５ｍｇ／ｋｇ后外周血中白细胞、单个核细胞（ｍｏｎｏｎｕｃｌｅａｒｃｅｋ,ＭＮＣ）、ＣＦＵ－ＧＭ、ＢＦＵ－Ｅ和ＣＦＵ－Ｍｉｘ产率等指标出现时相性变化。给药后１ｈ开始升高,２ｈ达到高峰、分别为药前值的２．２、２．６、３．８、４．４和３．０倍,７ｈ时趋向正常。给药后２ｈ上述各类细胞在外周血中的含量随着ＤＳ的剂量增加而增加。白细胞、ＭＮＣ计数在ＤＳ１８０ｍｇ／ｋｇ时达到峰值,均为对照组的４倍。２４０ｍｇ／ｋ８时未见明显增加。不同剂量ＤＳ对各系祖细胞均有不同程度的动员作用,ＤＳ剂量１５－３０ｍｇ／ｋｇ效果最好,每升血中ＣＦＵ－ＧＭ、ＢＦＵ－Ｅ、ＣＦＵ－Ｍｉｘ的数量分别相当于对照组的５．０、１１．９和８．８倍。其峰值出现时间与白细胞、ＭＮＣ不同,表明ＤＳ对不同类型细胞的作用机制也不尽一致。经口给小鼠投以ＤＳ２４０和４８ｏｍｇ／ｋｇ后,未见外周血中白细胞、ＭＮＣ计数有显著性升高,提示对造血干细胞没有动员作用。     

α受体激动对绵羊心肌瞬时性内向离子流的影响

用乙酰毒毛旋花子甙元（ＡＳ）０．０５μｍｏｌ／Ｌ诱发绵羊心浦肯野纤维产生稳定的瞬时性内向离子流（Ｉｔｉ）,用普萘洛尔０．５μｍｏｌ／Ｌ阻断β受体,观察α受体激动剂苯肾上腺素（ＰＥ）０．３,１．０μｍｏｌ／Ｌ对Ｉｔｉ幅值与时程的影响。ＰＥ１．０μｍｏｌ／Ｌ灌流２０,５０ｍｉｎ时Ｉｔｉ幅值分别由对照值１２．８±１．９ｎＡ减小至１０．７±１．２ｎＡ（ｎ＝５,Ｐ＜０．０５）与９．６±１．９ｎＡ（ｎ＝５,Ｐ＜０．０１）;ＩｔｉＤ５０时程分别由对照值１４５±２４．４ｍｓ延长至１８３．３±２８．１ｍｓ（ｎ＝５,Ｐ＜０．０５）与２０７．５±３４．２ｍｓ（ｎ＝５,Ｐ＜０．０１）,ＰＥ对Ｉｔｉ的抑制作用呈剂量依赖性与时间依赖性。Ｉｔｉ到达峰值的时间和回复到基线的时间都延长,提示ＰＥ作用下Ｉｔｉ通道动力学发生了变化。如果在β受体激动剂异丙肾上腺素（ＩＳＯ）１．０μｍｏｌ／Ｌ增强Ｉｔｉ的基础上,ＰＥ１．０μｍｏｌ／Ｌ灌流１０ｍｉｎ,对Ｉｔｉ幅值的抑制及时程的延长作用更显著,Ｉｔｉ幅值由对照值１５．６±３．２ｎＡ减小到１０．３±２．２ｎＡ;ＩｔｉＤ５０由９２．５±１４．３ｍｓ延长到１３２．５±３６．０ｍｓ（ｎ＝５,Ｐ＜０．０１）。     

新生大鼠脊髓薄片中的运动神经元对腹外侧索刺激的反应

在新生大鼠脊髓薄片细胞内记录了２５个经送行刺激鉴定的运动神经元（ＭＮ）,发现腹外侧索刺激可在８０％的ＭＮ诱发去极化反应（ＥＰＳＰ）。在静息电位水平ＥＰＳＰ的潜伏期、达峰时间、幅度、半衰时间和时程分别为１．２±０．２ｍｓ,２．６±０．４ｍｓ,１３±３ｍＶ,５．３±１．６ｍｓ和３１±８ｍｓ。ＥＰＳＰ呈等级性和膜电位依赖性,平均翻转电位为－８ｍＶ,潜伏期在０．—５Ｈｚ频率的刺激时相对恒定,但刺激频率＞２０Ｈｚ时ＥＰＳＰ变小或被取消。ＥＰＳＰ在低钙高镁溶液中被阻抑叵在无镁溶液中增强。犬尿烯酸（０．５—１ｍｍｏｌ／Ｌ）可逆地阻断ＥＰＳＰ,但氯胺酮（５０—１００μｍｏｌ／Ｌ）仅部分抑制之。结果表明腹外侧索中的下行纤维可能释放兴奋性氨基酸而激活ＭＮ。     

肾动脉内注射内皮素—1对麻醉大鼠肾神经传入放电的影响

本实验旨在观察肾动脉内注射ＥＴ－１对麻醉大鼠血压（ＢＰ）、心率（ＨＲ）和肾神经传入放电（ＡＲＮＡ）的影响,以及ＥＴＡ受体阻断剂ＢＱ－１２３和硝苯吡啶（Ｎｉｆ）对ＥＴ生物学效应的拮抗作用。结果如下：（１）肾动脉注射ＥＴ－１（１μｇ／ｋｇ）后,平均动脉压（ＭＡＰ）先有短暂的降低（由１３．７７±０．１３ｋＰａ降至１０．２±１．１２ｋＰａ）,随后为较显著的持久增高,增值达３．４４±１．６０ｋＰａＰ＜０．００１）,ＨＲ无明显变化,ＡＲＮＡ增加１０８．３３±１６．６７％（Ｐ＜０．００１）。（２）肾动脉内注射ＥＴＡ受体选择性拮抗剂ＢＱ－１２３（１５０μｇ／ｋｇ）,ＥＴ－１的上述效应即被拮抗。与ＥＴ组相比差异非常显著（Ｐ＜０．００１）。（３）肾动脉内注射二氢吡啶敏感性Ｌ－型钙通道阻断剂Ｎｉｆ（０．１ｍｇ／ｋｇ）,也可明显抑制ＥＴ－１的上述效应,与ＥＴ组相比差异十分显著（Ｐ＜０．００１）。以上结果表明：肾动脉内注射ＥＴ－１引起的麻醉大鼠ＭＡＰ增高和ＡＲＮＡ积分增加的作用,可能是由ＥＴＡ受体介导的,其作用的细胞机制可能在于胞内钙超载     

新型化学杂交剂GENESIS诱导小麦雄性不育的初步研究

ＧＥＮＥＳＩＳ是美国Ｍｏｎｓａｎｔｏ农业化学公司研制的一种新型小麦化学杂交剂。试验专门对其杀效果进行了初步研究。结果表明：以试的５个品种,在生育期Ｆｅｅｋｅｓ标准８．０－９．０时,用ＧＥＮＥＳＩＳ进行一次叶在喷施,３．０ｋｇ／ｈｍ＾２和５．０ｋｇ／ｈｍ＾２,剂量下,均可达到９９．０％以上的杀雄效果,人工饱和授粉证明ＧＥＮＳＥＳＩＳ对雌蕊的育性没有影响;     

Substituted phenyl as a steroid A-ring mimetic: Providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands

A class of arylsulfonamide glucocorticoid receptor agonists that contains a substituted phenyl group as a steroid A-ring mimetic is reported. The structural design and SAR that provide the functional switching of a GR antagonist to an agonist is described. A combination of specific hydrogen bonding and lipophilic elements on the A-ring moiety is required to achieve potent GR agonist activity. This study culminated in the identification of compound 23 as a potent GR agonist with selectivity over the PR and MR nuclear hormone receptors.     

The ecdysteroid receptor

Summary

The steroid molting hormone of insects and other arthropods regulates gene activity in target tissues through its association with a specific, high affinity receptor protein. In this review we summarize recent advances in several areas of ecdysteroid receptor research, including efforts to characterize and purify the receptor protein, cytochemical studies of its tissue distribution and subcellular localization during development, and current molecular genetic studies ecdysteroid action.     

雄激素和雌激素受体药物筛选方法的研究进展

雄激素和雌激素受体通过与相应激素特异性结合促进细胞分化和组织生长,发挥重要的生理功能,其功能失调可诱发多种疾病。雄激素和雌激素受体的选择性调节剂是治疗相关疾病的重要药物。基于基因组学、分子生物学、细胞生物学和生物信息学等最新研究成果而发展形成的实验技术或方法被用于新型雄激素和雌激素受体调节剂的筛选,显著加快了新药开发的进程。     

Analysis of 3D models of octopus estrogen receptor with estradiol: evidence for steric clashes that prevent estrogen binding

Relatives of the vertebrate estrogen receptor (ER) are found in Aplysia californica, Octopus vulgaris, Thais clavigera, and Marisa cornuarietis. Unlike vertebrate ERs, invertebrate ERs are constitutively active and do not bind estradiol. To investigate the molecular basis of the absence of estrogen binding, we constructed a 3D model of the putative steroid-binding domain on octopus ER. Our 3D model indicates that binding of estradiol to octopus ER is prevented by steric clashes between estradiol and amino acids in the steroid-binding pocket. In this respect, octopus ER resembles vertebrate estrogen-related receptors (ERR), which have a ligand-binding pocket that cannot accommodate estradiol. Like ERR, octopus ER also may have the activation function 2 domain (AF2) in a configuration that can bind to coactivators in the absence of estrogens, which would explain constitutive activity of octopus ER.     

降钙素基因相关肽家族受体及其受体活性修饰蛋白

降钙素基因相关肽家族是一类多功能的激素家族 ,参与人体的多种生物学功能 ,与多种疾病有关。降钙素基因相关肽受体包括降钙素受体 (CTR)和降钙素受体样受体 (CRLR) ,CTR可以独自与降钙素结合 ,而CRLR必须与一组称作受体活性修饰蛋白 (RAMPs)的蛋白质共同作用才能发挥生物学功能。综述CTR的研究概况及CRLR与RAMPs相互作用的机制和表达调控 ,以期为人们设计新型药物提供参考。     

新型抗抑郁药物分子靶标研究进展

抑郁症是一种严重的精神障碍疾病,其发病机制复杂。近年来随着对抑郁症发病机制的深入研究,发现了一些基于非单胺递质的 新型抗抑郁药物分子靶标。综述N -甲基-D-天冬氨酸（NMDA）受体、促肾上腺皮质激素释放因子（CRF）受体、阿片受体、γ-氨基丁 酸B(GABAB) 受体、乙酰胆碱受体等抗抑郁药物作用的新靶标及其相应分子机制研究进展,为开发高效、安全的抗抑郁症新药提供参考。     

Ago-Allosteric Modulation and Other Types of Allostery in Dimeric 7TM Receptors

Conventionally, an allosteric modulator is neutral in respect of efficacy and binds to a receptor site distant from the orthosteric site of the endogenous agonist. However, recently compounds being ago-allosteric modulators have been described i.e., compounds acting both as agonists on their own and as enhancers for the endogenous agonists in both increasing agonist potency and providing additive efficacy—superagonism. The additive efficacy can also be observed with agonists, which are neutral or even negative modulators of the potency of the endogenous ligand. Based on the prevailing dimeric concept for 7TM receptors, it is proposed that the ago-allosteric modulators bind in the orthosteric binding site, but–importantly–in the “other” or allosteric protomer of the dimer. Hereby, they can act both as additive co-agonists, and through intermolecular cooperative effects between the protomers, they may influence the potency of the endogenous agonist. It is of interest that at least some endogenous agonists can only occupy one protomer of a dimeric 7TM receptor complex at a time and thereby they leave the orthosteric binding site in the allosteric protomer free, potentially for binding of exogenous, allosteric modulators. If the allosteric modulator is an agonist, it is an ago-allosteric modulator; if it is neutral, it is a classical enhancer. Molecular mapping in hetero-dimeric class-C receptors, where the endogenous agonist clearly binds only in one protomer, supports the notion that allosteric modulators can act through binding in the “other” protomer. It is suggested that for the in vivo, clinical setting a positive ago-allosteric modulator should be the preferred agonist drug.     

Proteinase-activated receptors, nucleotide P2Y receptors, and μ-opioid receptor-1B are under the control of the type I transmembrane proteins p23 and p24A in post-Golgi trafficking

We recently characterized the proteinase-activated receptor (PAR)-2, a G protein-coupled receptor (GPCR), as the first cargo protein recognized by p24A. Here, we demonstrate that p24A binds to several other GPCRs, including PAR-1, the nucleotide receptors P2Y(1), P2Y(2), P2Y(4), and P2Y(11), as well as the μ-opioid receptor 1B. The acidic amino acid residues Glu and Asp at the second extracellular loop of GPCRs are essential for interaction with p24A. p23, another member of the p24 family, also interacts with GPCRs, similar to p24A. However, p23 shows a delayed dissociation from PAR-2 after activation of PAR-2, compared to the dissociation between PAR-2 and p24A. p24A and p23 arrest both P2Y(4) receptor and μ-opioid receptor 1B at the intracellular compartments, as observed for PAR-2. A comparable result was obtained when we studied primary rat astrocytes in culture. Over-expression of the N-terminal p24A fragment impairs PAR-2 resensitization in astrocytes that extends our findings to a native system. In summary, we demonstrate that p24A and p23 are specific cargo receptors of GPCRs and differentially control GPCR trafficking in the biosynthetic pathway, and thereby, p24A and p23 regulate GPCR signaling in astrocytes.     

The insulin-binding domain of insulin receptor is encoded by exon 2 and exon 3.

Insulin receptors are disulfide-linked oligotetramers composed of two heterodimers each containing a 130-kDa alpha subunit and a 90-kDa beta subunit. Insulin binds to the extracellular alpha subunit, and in the process stimulates the autophosphorylation of the beta subunit and the expression of tyrosine kinase activity. Studies combining the use of photoaffinity labeling and immunoprecipitation with anti-peptide antibody have directly demonstrated that the cysteine-rich domain, encoded by exon 3, in the alpha subunit is part of the insulin-binding site of the receptor. Experiments with chimeric insulin receptors and chimeric insulin-like growth factor I receptors have confirmed that the cysteine-rich domain constitutes a part of the insulin-binding site. In addition, results from these experiments suggest that the N-terminal sequence, encoded by exon 2, in the alpha subunit also participates in insulin binding. In this review it is proposed that, assuming two insulin-binding sites per each holoreceptor oligotetramer, each insulin-binding domain may contain respectively two sub-domains for hydrophobic and charge contact with insulin, and that high-affinity binding would require the interaction of both subunits with the possibility of each subunit reciprocally contributing one of the sub-domains.